Giant Biogene Holding (02367) Report Interpretation

Overview

This earnings review assesses Giant Biogene’s 1H26 results, the effect of elevated selling and branding investment on margins, and the outlook for a sales recovery in 2H26. Goldman Sachs maintains Buy, while reducing longer-dated earnings estimates and its target price modestly.

Core views

Giant Biogene’s 1H26 results showed a mixed earnings picture. Revenue fell 6.3% year on year to RMB2.918bn, which was 1% above Goldman Sachs estimates and 2% above Visible Alpha consensus, mainly because Comfy performed better than expected. Gross margin declined 2.2 percentage points year on year to 79.5%, but was 0.8 percentage points above Goldman Sachs estimates. The main shortfall was operating expenses: selling and distribution expenses rose 19.7% year on year to RMB1.267bn, 9.4% above Goldman Sachs estimates, and the selling-expense ratio rose 9.4 percentage points to 43.4%, 3.4 percentage points above estimate. Consequently, operating profit fell 31.9% to RMB926m and operating margin contracted 11.9 percentage points to 31.7%; operating profit was 7% below Goldman Sachs estimates and 8% below consensus. Net income was more resilient than operating profit. Net profit attributable to shareholders declined 20.5% year on year to RMB940m, but was 1% above Goldman Sachs estimates and 2% above consensus. Higher interest income lifted non-operating gains by 88.7% year on year to RMB159m, while the effective tax rate of 14.2% was below Goldman Sachs’ 18.1% estimate. These items offset the operating-profit miss, leaving net margin at 32.2%, 0.2 percentage points above Goldman Sachs estimates. At the operating level, professional skin-treatment-product sales declined 6.2% to RMB2.910bn. Comfy sales fell 8% to RMB2.347bn, representing 80% of sales and running 3% above Goldman Sachs estimates, while Collgene sales fell 1% to RMB499m and were 10% below estimate. Cosmetics sales fell 5% to RMB2.301bn and represented 79% of sales; medical-device sales decreased 12% to RMB610m and represented 21%. Direct sales declined 4% to RMB2.234bn, with online DTC down 2%, online e-commerce-platform sales down 14%, and offline direct sales up 4%. Distribution sales declined 13% to RMB683m. Goldman Sachs’ tracker indicated that Comfy and Collgene online GMV grew 8% and 23% year on year in July, respectively, which it views as signs of a gradual recovery. Goldman Sachs remains cautious on the 2H26 operating-margin trajectory because overall demand is softer and online competition remains intense among global and local peers. Its cosmetics tracker showed online-industry growth slowing to 5% year on year in July from 11% in 2Q26. Nevertheless, the report retains its 2026 full-year key-line forecasts and expects robust 2H26 sales growth of 31% year on year, driven by new-product and business-line scaling. Goldman Sachs characterizes the investment as a necessary effort to build consumer mind-share for the longer term. Following the results, Goldman Sachs keeps 2026E net income roughly unchanged but lowers 2027E–28E net income by approximately 5%. Higher projected selling expenses from competition and branding investment outweigh slightly higher revenue assumptions from better Comfy performance. Higher 2026 other income and gains, including interest income and a lower tax rate, partly offset the increased expense. The revised estimates call for 2H26 sales of RMB3.1bn and net income of RMB937m, up 31% and 28% year on year, respectively. The target P/E exit multiple remains 17x 2027E because Goldman Sachs considers the growth trajectory consistent with its prior view. The 12-month target price is reduced to HK$33 from HK$34 after the earnings revisions. It is based on 17x 2027E P/E discounted back to end-2026E using a 9.6% cost of equity. The 17x multiple is derived from a 50/50 blend of cosmetics and medical-devices P/E multiples after a 20% A-H share discount: the cosmetics reference multiple is 20x and the medical-devices reference multiple is 22x. Goldman Sachs maintains Buy; shares were trading at 14x 2026E P/E, in line with the one-year average of 14x.

Analysis framework

Goldman Sachs compares reported 1H26 revenue, margins, operating profit and net profit with its own estimates and Visible Alpha consensus, then traces variances by brand, product category, channel and expense line. It uses online-GMV tracker data to assess demand and recovery, revises earnings forecasts for sales, expenses, interest income and taxes, and values the company on a forward P/E exit multiple discounted by its cost of equity.

Methodology notes

• Industry AnalysisVolume-price decomposition

  Brand, category and channel operating analysis

  The report breaks revenue performance across Comfy, Collgene, product categories and sales channels to identify the sources of the 1H26 result and the expected recovery.

• Valuation methodsP/E and PEG Valuation

  Forward P/E exit-multiple valuation

  The HK$33 target price uses a 17x 2027E P/E exit multiple, discounted back to end-2026E using a 9.6% cost of equity; the multiple is blended from cosmetics and medical-devices reference multiples.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Giant Biogene Holding (2367.HK)

  Primary covered company; Goldman Sachs maintains Buy following 1H26 results.

  Strengths

  Comfy outperformed Goldman Sachs estimates; July online GMV growth for Comfy and Collgene suggested gradual recovery; 2H26 growth is expected to be supported by new products and business lines.

  Weaknesses

  1H26 sales declined, operating profit missed estimates, and margins were pressured by higher selling expenses.

  Comparison

  Shares traded at 14x 2026E P/E, in line with the one-year average of 14x; the valuation uses blended cosmetics and medical-devices P/E reference multiples.

  Risks

  Slower-than-expected professional skin-treatment-market growth, intensified competition, unsuccessful product development and regulatory risk.

Key data

• 1H26 revenueRMB2,917.7mnDown 6.3% year on year; 1% above Goldman Sachs estimates and 2% above Visible Alpha consensus.
• 1H26 operating profitRMB926.2mnDown 31.9% year on year; 7% below Goldman Sachs estimates and 8% below consensus.
• 1H26 operating margin31.7%Down 11.9 percentage points year on year; 2.6 percentage points below Goldman Sachs estimates.
• 1H26 net profit attributable to shareholdersRMB939.7mnDown 20.5% year on year; 1% above Goldman Sachs estimates and 2% above consensus.
• Selling and distribution expensesRMB1,267mnUp 19.7% year on year; expense ratio rose 9.4 percentage points to 43.4%.
• 2H26 forecastRMB3.1bn sales and RMB937mn net incomeGoldman Sachs expects year-on-year growth of 31% in sales and 28% in net income.
• Target priceHK$33Reduced from HK$34; based on 17x 2027E P/E discounted using a 9.6% cost of equity.

Impact & implications

The report views heavier spending as the near-term drag on operating margins but also as support for new-product launches and longer-term consumer mind-share. A recovery in demand and brand-level growth is central to the expected strong 2H26 sales rebound, while the lower medium-term earnings estimates reflect the expectation that competition and branding investment will remain elevated.

Risks

• Slower-than-expected growth or intensified competition in the professional skin treatment market.
• Inability to develop successful products.
• Regulatory risk.

What to watch

• 2H26 growth and margin outlook by brand and SKU.
• Branding investment, return-on-investment trends and channel strategy in 2H26.
• Product roll-out progress, early market feedback and channel strategy for the medical-aesthetics business.